Device Trial Radar · NCT00348205
A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
Last checked: Nov 20, 2026Latest source record: Sep 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jun 2005
Primary completion
Jan 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 4, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to demonstrate the safety and effectiveness of wavefront laser refractive surgery treatments for hyperopia and astigmatism.
Conditions
- Hyperopia
- Astigmatism
Interventions
Technolas 217z Zyoptix LaserDevice
Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 MonthsTime frame: 24 months
- Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.Time frame: 12 months
- The Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of EmmetropiaTime frame: 24 months
3 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.